Presage Biosciences raises $13M and inks new deal with Merck for cancer drug tests
March 4, 2021 at 3:30 pm
Presage CEO Richard Klinghoffer. (Presage Photo)
New funds, new partners: Seattle’s Presage Biosciences announced $13 million in funding as well new collaborations with biotech giant Merck and California-based Maverick Therapeutics. Presage is a biotech device company that has built a platform for testing new cancer drugs used to treat tumors.
Presage has existing partnerships with healthcare heavy hitters Takeda Pharmaceutical, Celgene and Bristol Myers Squibb (BMS). The company has raised a total of $35 million in equity, and this its first venture round.
Quicker, cheaper drug screening: Before a cancer drug is given to patients in phase I trials, it’s first tested in the lab. But many of the drugs that appear to hold promise in that setting don’t perform well when marshaled against actual tumors in people.
NEW YORK, N.Y., Jan 08, 2021 (SEND2PRESS NEWSWIRE) DDK & Company, LLP, an accounting, tax, and consulting firm, announced on January 1 that Sze Man Tam has been promoted to Partner. In her new role, Sze will be leading DDK’s Audit department, helping clients grow and improve their businesses, and developing DDK’s next generation.
Sze started her career as a Junior Accountant in 2004, was promoted to Assurance Manager, and is now a Partner. She is a member of the New York State Society of Certified Public Accountants and the American Institute of Certified Public Accountants. Sze has a wide variety of expertise including non-profits, real estate, manufacturing, distributions and wholesalers, art galleries, jewelry, and employee benefits plans.
DDK and Company Welcomes Sze Man Tam as Partner: First Asian-American to Take on this Role greensburgdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from greensburgdailynews.com Daily Mail and Mail on Sunday newspapers.